Header Logo

NATALIA LAPTEVA

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pathology & Immunology
Address1102 BATES
Houston, TX 77030
vCardDownload vCard
    Other Positions
    TitleAssociate Professor
    InstitutionBaylor College of Medicine
    DepartmentCenter for Cell & Gene Therapy
    DivisionCenter for Cell & Gene Therapy


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hill LC, Rouce RH, Wu M, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla PD, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M, Hill LC, Rouce RH, Wu MJ, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla P, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin M. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241. PMID: 38145560; PMCID: PMC10997912.
      Citations:    Fields:    Translation:HumansCells
    2. Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla P. Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850. PMID: 36373249; PMCID: PMC10316279.
      Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
    3. Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113. PMID: 35860837; PMCID: PMC9290161.
      Citations:    
    4. Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HE. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24. PMID: 35325065; PMCID: PMC9346960.
      Citations:    Fields:    Translation:HumansCells
    5. Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PD. Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711. PMID: 35134127; PMCID: PMC9053698.
      Citations: 1     Fields:    Translation:Humans
    6. Ibenana L, Anderson R, Gee A, Gilbert M, Cox C, Hare JM, Brooks A, Kelley L, Khan A, Lapteva N, Orozco A, Styers D, Sumstad D, Ugochi I, McKenna DH. Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study. Cytotherapy. 2022 07; 24(7):691-698. PMID: 35279374; PMCID: PMC9232931.
      Citations:    Fields:    Translation:Cells
    7. Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance RA, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350. PMID: 31558475; PMCID: PMC7062259.
      Citations: 13     Fields:    Translation:HumansCells
    8. Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Cancer Immunol Res. 2019 03; 7(3):363-375. PMID: 30651290; PMCID: PMC7906796.
      Citations: 83     Fields:    Translation:HumansAnimalsCells
    9. Omer B, Castillo PA, Tashiro H, Shum T, Huynh MTA, Cardenas M, Tanaka M, Lewis A, Sauer T, Parihar R, Lapteva N, Schmueck-Henneresse M, Mukherjee M, Gottschalk S, Rooney CM. Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2018; 5:343. PMID: 30619856; PMCID: PMC6297364.
      Citations: 3     
    10. Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL. Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232. PMID: 28864289.
      Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
    11. Omer B, Shum T, Tashiro H, Mamonkin M, Lapteva N, Sharma S, Rollins L, Dotti G, Rooney CM, Schmueck-Henneresse M, Reinke P, Volk HD. Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. J Immunol. 2017 07 01; 199(1):348-362. PMID: 28550199; PMCID: PMC5536854.
      Citations: 22     Fields:    Translation:HumansCells
    12. Lapteva N, Parihar R, Rollins LA, Gee AP, Rooney CM. Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy. Methods Mol Biol. 2016; 1441:195-202. PMID: 27177667.
      Citations: 8     Fields:    Translation:HumansCells
    13. Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM. Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5. PMID: 25734008; PMCID: PMC4346112.
      Citations: 17     Fields:    
    14. Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F, Szmania S. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36. PMID: 25415285; PMCID: PMC4352951.
      Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
    15. Miller JS, Rooney CM, Curtsinger J, McElmurry R, McCullar V, Verneris MR, Lapteva N, McKenna D, Wagner JE, Blazar BR, Tolar J. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant. 2014 Aug; 20(8):1252-7. PMID: 24816582; PMCID: PMC4099265.
      Citations: 40     Fields:    Translation:HumansAnimalsCells
    16. Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM, Ngo MC. Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity. J Immunother. 2014 May; 37(4):193-203. PMID: 24714353; PMCID: PMC4133102.
      Citations: 28     Fields:    Translation:HumansCells
    17. Lapteva N, Szmania SM, van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog. 2014; 19(1-2):121-32. PMID: 24941378; PMCID: PMC4095851.
      Citations: 22     Fields:    Translation:HumansCells
    18. Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012 Oct; 14(9):1131-43. PMID: 22900959; PMCID: PMC4787300.
      Citations: 91     Fields:    Translation:HumansCells
    19. Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, Lapteva N, Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH. Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314. PMID: 22004414; PMCID: PMC3198747.
      Citations: 48     Fields:    Translation:HumansCells
    20. Lapteva N, Vera JF. Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int. 2011; 2011:434392. PMID: 21915183; PMCID: PMC3170896.
      Citations: 8     
    21. Chiou SH, Shahi P, Wagner RT, Hu H, Lapteva N, Seethammagari M, Sun SC, Levitt JM, Spencer DM. The E3 ligase c-Cbl regulates dendritic cell activation. EMBO Rep. 2011 Sep 01; 12(9):971-9. PMID: 21799517; PMCID: PMC3166462.
      Citations: 8     Fields:    Translation:AnimalsCells
    22. Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM. A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Invest. 2011 Apr; 121(4):1524-34. PMID: 21383499; PMCID: PMC3069772.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    23. Ramachandran IR, Song W, Lapteva N, Seethammagari M, Slawin KM, Spencer DM, Levitt JM. The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol. 2011 Apr 01; 186(7):3934-45. PMID: 21357539.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    24. Lapteva N, Huang XF. CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther. 2010 May; 10(5):725-33. PMID: 20233026.
      Citations: 38     Fields:    Translation:HumansAnimals
    25. Lapteva N. Enhanced migration of human dendritic cells expressing inducible CD40. Methods Mol Biol. 2010; 651:79-87. PMID: 20686961.
      Citations:    Fields:    Translation:HumansCells
    26. Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther. 2009 Sep; 17(9):1626-36. PMID: 19532135; PMCID: PMC2835257.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    27. Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother. 2009 Feb-Mar; 32(2):145-56. PMID: 19238013; PMCID: PMC4146345.
      Citations: 42     Fields:    Translation:AnimalsCells
    28. Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 2007 Nov 01; 67(21):10528-37. PMID: 17974997.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    29. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol. 2006 Dec; 24(12):1581-90. PMID: 17143278.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    30. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther. 2005 Jan; 12(1):84-9. PMID: 15472715.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    LAPTEVA's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (181)
    Explore
    _
    Co-Authors (35)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _